Search Follow us


Management believes that Deinove now has the necessary financial resources to continue with its work until the end of FY17 without recourse to further equity funding. Deinove will continue to progress towards commercialising its technology in both the Deinochem and Deinol projects, with first commercial revenues expected by 2018. Based on the assumption that it can successfully deploy its technology, we believe Deinove could be worth c €8/share (previously €10).

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs